Today marks TargetCancer Foundation’s 16th Anniversary!
On this day in 2009, our founder Paul Poth filed the papers for TargetCancer Foundation to become an official 501c3 non-profit organization. Paul envisioned an organization that focused on cancers like his that received little research funding and attention just because they were rare. Two months later, he awarded TCF’s first grant of $7,500 to the Center for Molecular Therapeutics at Massachusetts General Hospital. Over the past 16 years, TCF has funded over $2 million in rare cancer research, launched TRACK, a remote precision medicine rare cancer clinical trial, convened stakeholders at our annual scientific Think Tanks and Industry Roundtable meetings, and assisted patients and families facing rare cancers. In recent months, we have created and published new educational materials to assist patients and families who are facing a rare cancer diagnosis.
We are so proud of our achievements but know we have much more work to do to address the many challenges that are shared across all rare cancers. We are grateful for this community of support over these past 16 years and look forward to continuing to work together as we grow in 2025 and beyond!
Watch a brief video about the history of TCF and our work here.
Read more about our founding here.